CO2017005574A2 - Composiciones anticancerígenas que comprenden 4-[7-(6-ciano-5- trifluorometilpiridin-3-ilo)-8-oxo-6-tioxo-5,7-diazaspiro[3.4]oct-5-ilo]-2-fluoro-nmetilbenzamida, un copolímero de poli(met)acrilato y hpmcas - Google Patents

Composiciones anticancerígenas que comprenden 4-[7-(6-ciano-5- trifluorometilpiridin-3-ilo)-8-oxo-6-tioxo-5,7-diazaspiro[3.4]oct-5-ilo]-2-fluoro-nmetilbenzamida, un copolímero de poli(met)acrilato y hpmcas

Info

Publication number
CO2017005574A2
CO2017005574A2 CONC2017/0005574A CO2017005574A CO2017005574A2 CO 2017005574 A2 CO2017005574 A2 CO 2017005574A2 CO 2017005574 A CO2017005574 A CO 2017005574A CO 2017005574 A2 CO2017005574 A2 CO 2017005574A2
Authority
CO
Colombia
Prior art keywords
hpmcas
meth
acrylate
copolymer
poly
Prior art date
Application number
CONC2017/0005574A
Other languages
English (en)
Inventor
Geert Verreck
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52006907&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017005574(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of CO2017005574A2 publication Critical patent/CO2017005574A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a formulaciones farmacéuticas de ARN-509, que pueden administrarse a un mamífero, particularmente, a un ser humano, que sufre una enfermedad o afección relacionada con un receptor de andrógenos (AR), particularmente, cáncer, más particularmente, cáncer de próstata, que incluye, pero sin limitarse al cáncer de próstata resistente a castración, cáncer de próstata metastásico resistente a castración, cáncer de próstata metastásico resistente a castración sin previo tratamiento quimioterapéutico, cáncer de próstata sensible a hormona bioquímicamente reincidido o de alto riesgo, cáncer de próstata no metastásico resistente a castración. En un aspecto, estas formulaciones comprenden una dispersión sólida de ARN-509, un copolímero depoli(met)acrilato y HPMCAS. En un aspecto, la dispersión sólida de ARN-509, un copolímero de poli(met)acrilato y HPMCAS puede obtenerse y particularmente, se obtiene por extrusión por fusión de una mezcla que comprende ARN-509 un copolímero de poli(met)acrilato y HPMCAS y opcionalmente posterior molido de dicha mezcla extrudida por fusión. En un aspecto, la dispersión sólida de ARN-509, un copolímero de poli(met)acrilato y HPMCAS puede obtenerse y particularmente, se obtiene por secado por aspersión de una mezcla que comprende ARN-509, un copolímero de poli(met)acrilato y HPMCAS en un solvente adecuado.
CONC2017/0005574A 2014-12-05 2017-06-05 Composiciones anticancerígenas que comprenden 4-[7-(6-ciano-5- trifluorometilpiridin-3-ilo)-8-oxo-6-tioxo-5,7-diazaspiro[3.4]oct-5-ilo]-2-fluoro-nmetilbenzamida, un copolímero de poli(met)acrilato y hpmcas CO2017005574A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14196605 2014-12-05
PCT/US2015/063671 WO2016090105A1 (en) 2014-12-05 2015-12-03 Anticancer compositions

Publications (1)

Publication Number Publication Date
CO2017005574A2 true CO2017005574A2 (es) 2017-09-29

Family

ID=52006907

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0005574A CO2017005574A2 (es) 2014-12-05 2017-06-05 Composiciones anticancerígenas que comprenden 4-[7-(6-ciano-5- trifluorometilpiridin-3-ilo)-8-oxo-6-tioxo-5,7-diazaspiro[3.4]oct-5-ilo]-2-fluoro-nmetilbenzamida, un copolímero de poli(met)acrilato y hpmcas

Country Status (33)

Country Link
US (3) US10285948B2 (es)
EP (2) EP3226843B1 (es)
JP (1) JP6830892B2 (es)
KR (1) KR102387089B1 (es)
CN (1) CN106999432A (es)
AR (1) AR102925A1 (es)
AU (1) AU2015358497B2 (es)
CA (1) CA2969675C (es)
CL (1) CL2017001373A1 (es)
CO (1) CO2017005574A2 (es)
CR (1) CR20170218A (es)
CY (1) CY1124504T1 (es)
DK (1) DK3226843T3 (es)
EA (1) EA201791251A1 (es)
ES (1) ES2883187T3 (es)
HR (1) HRP20211140T1 (es)
HU (1) HUE054935T2 (es)
IL (1) IL252325A0 (es)
LT (1) LT3226843T (es)
MA (1) MA41111B1 (es)
MD (1) MD3226843T2 (es)
MX (1) MX2017007206A (es)
MY (1) MY192931A (es)
NI (1) NI201700068A (es)
PH (1) PH12017500979A1 (es)
PL (1) PL3226843T3 (es)
PT (1) PT3226843T (es)
RS (1) RS62421B1 (es)
SG (1) SG11201704386VA (es)
SI (1) SI3226843T1 (es)
TW (1) TWI709403B (es)
UA (1) UA123538C2 (es)
WO (1) WO2016090105A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202190820A1 (ru) 2012-09-26 2021-10-29 Арагон Фармасьютикалз, Инк. Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
SI3226843T1 (sl) 2014-12-05 2021-11-30 Aragon Pharmaceuticals, Inc. Protirakavi sestavki
WO2019078920A1 (en) 2017-10-16 2019-04-25 Aragon Pharmaceuticals, Inc. ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC RESISTANT PROSTATE CANCER
WO2020144646A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Apalutamide dispersed in applesauce for treating prostate cancer
AU2020215177A1 (en) 2019-01-30 2021-08-12 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
JP2022523094A (ja) 2019-01-30 2022-04-21 アラゴン ファーマシューティカルズ，インコーポレイテッド 転移性去勢感受性前立腺癌の治療のための抗アンドロゲン剤
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CA3160121A1 (en) 2019-11-04 2021-05-14 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
TW202228794A (zh) 2020-09-04 2022-08-01 美商艾瑞岡醫藥公司 用於治療前列腺癌之方法
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0633893T3 (da) 1992-03-31 2000-04-17 Btg Int Ltd 17-Substituerede steroider, der er nyttige ved cancerbehandling
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
CA2400845A1 (en) 2000-02-21 2001-08-23 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active compound slightly soluble in water and production process and use of the same
DE60206889T2 (de) 2001-02-27 2006-07-27 Astrazeneca Ab Pharmazeutische formulierung enthaltend bicalutamid
ES2261655T3 (es) 2001-04-02 2006-11-16 Astrazeneca Ab Composicion farmaceutica solida que comprende 4'-ciano-trifluoro-3-(4-fluorofenilsulfonil)-2-hidroxi-2-metilpropiono-m-toluiduro y pvp.
TNSN03137A1 (en) 2001-06-22 2005-12-23 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS COMPRISING LOW SOLUBILITY AND / OR ACID SENSITIVE DRUGS AND NEUTRALIZED ACID POLYMERS.
SE0103424D0 (sv) 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
CA2474958A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
WO2003077827A1 (fr) 2002-03-19 2003-09-25 Nippon Shinyaku Co., Ltd. Procede de production de medicament solide en dispersion
JP2007518670A (ja) 2003-12-15 2007-07-12 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 苦味のある薬物、及びｐＨ感受性ポリマーを含む風味マスクされた医薬組成物
DK2656842T3 (en) 2006-03-27 2016-11-07 Univ California Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES
ES2552386T3 (es) * 2009-04-03 2015-11-27 F. Hoffmann-La Roche Ag Composiciones de {3-[5-(4-cloro-fenil)-1H-pirrol[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propano-1-sulfónico y usos de las mismas
MX355915B (es) 2010-02-16 2018-05-04 Aragon Pharmaceuticals Inc Moduladores del receptor de androgenos y usos de los mismos.
CN102525876B (zh) * 2010-12-15 2014-03-12 西安力邦医药科技有限责任公司 阿司匹林固体分散体、其制备方法、药物组合物和用途
CA2839301C (en) 2011-06-15 2021-02-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nuclear receptor modulators and their use for the treatment and prevention of cancer
US20150037407A1 (en) 2012-03-21 2015-02-05 Emphascience, Inc. Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy
WO2013152342A1 (en) * 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
EP2858985B1 (en) 2012-06-07 2018-04-18 Aragon Pharmaceuticals, Inc. Crystalline forms of an androgen receptor modulator
US10668156B2 (en) 2012-06-22 2020-06-02 Basf Se Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
MX2015002430A (es) 2012-08-24 2015-06-22 Dow Global Technologies Llc Acetato-succinatos de hidroxialquilmetilcelulosa.
RS62676B1 (sr) * 2012-09-11 2021-12-31 Medivation Prostate Therapeutics Llc Formulacije enzalutamida
US9977033B2 (en) 2012-09-11 2018-05-22 The Board Of Regents Of The University Of Texas System Methods for assessing cancer recurrence
EA202190820A1 (ru) * 2012-09-26 2021-10-29 Арагон Фармасьютикалз, Инк. Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EP2948141A1 (en) 2013-01-22 2015-12-02 F. Hoffmann-La Roche AG Pharmaceutical composition with improved bioavailability
JP2016514707A (ja) 2013-03-15 2016-05-23 アイシューティカ インク．Ｉｃｅｕｔｉｃａ Ｉｎｃ． アビラテロン酢酸エステル製剤
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US9566280B2 (en) * 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
KR20200015830A (ko) * 2014-02-05 2020-02-12 레크 파마슈티칼스 디.디. 안드로겐 수용체 길항제의 고체 제약 조성물
EP3102595B1 (en) 2014-02-06 2018-11-07 F.Hoffmann-La Roche Ag Interleukin-2 fusion proteins and uses thereof
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
MA41107A (fr) 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
LT3226842T (lt) 2014-12-05 2021-03-25 Aragon Pharmaceuticals, Inc. Priešvėžinės kompozicijos
SI3226843T1 (sl) 2014-12-05 2021-11-30 Aragon Pharmaceuticals, Inc. Protirakavi sestavki
CN109219437A (zh) * 2016-06-03 2019-01-15 阿拉贡药品公司 抗癌组合物

Also Published As

Publication number Publication date
JP2017536407A (ja) 2017-12-07
NI201700068A (es) 2017-09-11
JP6830892B2 (ja) 2021-02-17
PH12017500979A1 (en) 2017-11-27
US11224575B2 (en) 2022-01-18
UA123538C2 (uk) 2021-04-21
EP3226843A1 (en) 2017-10-11
TW201636019A (zh) 2016-10-16
US11911511B2 (en) 2024-02-27
EP3226843B1 (en) 2021-05-26
EA201791251A1 (ru) 2017-11-30
ES2883187T3 (es) 2021-12-07
CY1124504T1 (el) 2022-07-22
SI3226843T1 (sl) 2021-11-30
RS62421B1 (sr) 2021-10-29
SG11201704386VA (en) 2017-06-29
MA41111B1 (fr) 2021-09-30
CA2969675C (en) 2023-06-06
KR102387089B1 (ko) 2022-04-14
CN106999432A (zh) 2017-08-01
IL252325A0 (en) 2017-07-31
PL3226843T3 (pl) 2021-12-13
AR102925A1 (es) 2017-04-05
AU2015358497B2 (en) 2021-04-29
EP3925598A1 (en) 2021-12-22
DK3226843T3 (da) 2021-08-16
AU2015358497A1 (en) 2017-06-08
TWI709403B (zh) 2020-11-11
KR20170086658A (ko) 2017-07-26
MX2017007206A (es) 2018-01-30
CA2969675A1 (en) 2016-06-09
HUE054935T2 (hu) 2021-10-28
MD3226843T2 (ro) 2021-10-31
PT3226843T (pt) 2021-07-07
HRP20211140T1 (hr) 2021-10-15
CR20170218A (es) 2017-08-30
US20190209477A1 (en) 2019-07-11
US20170360713A1 (en) 2017-12-21
US20210308060A1 (en) 2021-10-07
BR112017011726A2 (pt) 2017-12-26
US10285948B2 (en) 2019-05-14
MY192931A (en) 2022-09-15
LT3226843T (lt) 2021-08-10
WO2016090105A1 (en) 2016-06-09
CL2017001373A1 (es) 2018-01-05

Similar Documents

Publication Publication Date Title
CO2017005574A2 (es) Composiciones anticancerígenas que comprenden 4-[7-(6-ciano-5- trifluorometilpiridin-3-ilo)-8-oxo-6-tioxo-5,7-diazaspiro[3.4]oct-5-ilo]-2-fluoro-nmetilbenzamida, un copolímero de poli(met)acrilato y hpmcas
CO2017005573A2 (es) Composiciones anticancerígenas que comprenden 4-[7-(6-ciano-5-trifluorometilpiridin-3-ilo)-8-oxo-6-tioxo-5,7-diazaspiro[3.4]oct-5-il]-2-fluoro-nmetilbenzamida y un copolímero de poli(met)acrilato”
CO2017005572A2 (es) Composiciones anticancerígenas
NZ722326A (en) Tricyclic compounds as anticancer agents
NI201800127A (es) Composiciones antineoplásicas
NZ728392A (en) High dosage strength tablets of rucaparib
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
MX2017013142A (es) Terapia combinada para tratar cáncer.
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
CL2008003846A1 (es) Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata.
EA201170940A1 (ru) Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
UY32822A (es) Composiciones farmacéuticas para el tratamiento de cáncer y otras enfermedades o trastornos
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
SA516370388B1 (ar) ملح جديد من 3-[(3-{[4-(4-مورفولينيل ميثيل)-1h-بيرول-2-yl]ميثيلين}-2-أوكسو-3,2-ثنائي هيدرو-1h-إندول-5-yl)ميثيل]-3,1-ثيازوليدين-4,2-ديون، وعملية تحضيره، والتركيبات المحتوية عليه
GB2519470A (en) Bicyclic aza compounds as muscarinic M1 receptor agonists
CL2008001216A1 (es) Compuestos derivados de pirazol-3-il-amino-pirimidina; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer.